文献速递性腺与生殖内分泌糖尿病肥胖与代谢综合征

男性中枢性性早熟:GnRH类似物治疗与否对成年中期生育和健康无影响

Central Precocious Puberty in Males, GnRH Analog Treated or Untreated, Did Not Impact Fertility and Health in Midadulthood.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

结果显示,治疗组与未治疗组在生殖问题、代谢疾病、心血管疾病、骨骼健康、精神心理疾病及恶性肿瘤的患病率上均无显著差异,且ICPP患者与各自对照组健康结局相当。结论认为男性ICPP史无论是否治疗均未见与成年中期不良健康结局相关。

要点

  • 男性ICPP史无论是否接受GnRH类似物治疗,成年中期生殖与代谢结局均与一般人群相似。
  • 治疗组与未治疗组在生殖问题、代谢病、心血管病、骨健康、精神心理及肿瘤患病率上无显著差异。
  • 该研究提示男性ICPP的长期健康风险可能被高估,但需更多前瞻性研究验证。

核心结论

  • 男性特发性中枢性性早熟(ICPP)史,无论是否接受GnRH类似物治疗,均未显示与成年中期生殖、代谢、情感或肿瘤健康的不良结局相关。
  • 有ICPP史的成年男性总体健康特征与一般人群相似。

研究设计与样本

  • 数据来自Clalit健康服务数据库,包括人口学、病史、用药记录、人体测量数据和实验室结果。

主要发现

  • 治疗组与未治疗组在生殖问题患病率上无显著差异(11.8% vs 18.4%,P = .317)。
  • 治疗组与未治疗组在代谢疾病患病率上无显著差异(35.3% vs 34.7%,P = .946)。
  • 治疗组与未治疗组在心血管疾病患病率上无显著差异(16.2% vs 14.3%,P = .780)。
  • 治疗组与未治疗组在骨骼健康问题患病率上无显著差异(4.4% vs 4.1%,P = .931)。
  • 治疗组与未治疗组在精神心理疾病患病率上无显著差异(19.1% vs 16.3%,P = .698),恶性肿瘤患病率也无显著差异(1.5% vs 8.2%,P = .160)。

关键数值与推荐

  • 治疗组与未治疗组中位年龄分别为40岁和44岁(P < .001)。
  • ICPP患者与各自对照组在生殖和健康结局上相当,与治疗史无关。

临床怎么用

  • 对于男性ICPP患者,无论是否接受GnRH类似物治疗,长期健康监测可参考一般人群,无需过度担忧生殖、代谢、情感或肿瘤风险。
  • 临床咨询时可告知患者男性ICPP史与成年中期不良健康结局无明确关联。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 样本量有限,尤其是未治疗组仅50例,可能影响统计效能。
  • 中位年龄治疗组40岁、未治疗组44岁,随访时间差异可能影响结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The long-term health consequences of idiopathic central precocious puberty (ICPP) in males, whether treated or untreated, are not well established. OBJECTIVE: To evaluate general health and metabolic outcomes in adult men with a history of ICPP. DESIGN: Retrospective cohort study with age, birth year, and socioeconomic status-matched controls. PATIENTS: One hundred eighteen men aged 29 to 48 years with a history of ICPP (68 GnRH analog treated, 50 untreated) and 351 matched controls (204 matched to the treated group and 147 to the untreated group). METHODS: Data were extracted from the Clalit Health Services database and included demographics, medical history, medication records, anthropometric data, and laboratory results. MAIN OUTCOME MEASURES: Prevalence of reproductive issues, metabolic conditions (obesity, hypertension, hyperlipidemia, diabetes), osteoporosis, malignancy, and psychopathology. RESULTS: The median age was 40 years in the treated and 44 years in the untreated ICPP group (P < .001). No significant differences were observed between treated and untreated groups in the prevalence of reproductive issues (11.8% vs 18.4%, P = .317), metabolic disorders (35.3% vs 34.7%, P = .946), cardiovascular conditions (16.2% vs 14.3%, P = .780), bone health problems (4.4% vs 4.1%, P = .931), psychopathology (19.1% vs 16.3%, P = .698), or malignancies (1.5% vs 8.2%, P = .160). Reproductive and health outcomes were also comparable between ICPP patients and their respective control groups, regardless of treatment history. CONCLUSION: A history of ICPP in males, whether treated or untreated, does not appear to be associated with adverse long-term outcomes in reproductive, metabolic, emotional, or oncological health. Overall, adult men with prior ICPP exhibit similar health profiles to those of the general population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lazar L, Oron T, Yackobovitch-Gavan M, et al. Central Precocious Puberty in Males, GnRH Analog Treated or Untreated, Did Not Impact Fertility and Health in Midadulthood. J Clin Endocrinol Metab. 2025. PMID: 40720580. doi:10.1210/clinem/dgaf427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。